🧪 TrialInsufficient
Registered N/A interventional trial (completed). Obesity is a chronic condition linked to numerous health risks and affects more than one billion people worldwide. While pharmacological treatments such as incretin-based therapies are available, they may have side effects, are not suitable for all patients, and adherence can be limited. Dietary supplements that influence appetite and satiety may represent an alternative or complementary approach. This study will evaluate whether a dietary supplement containing plant extracts stimulates the intestinal incretin response. The primary focus is the
ClinicalTrials.gov · Nov 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (active not recruiting). The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
ClinicalTrials.gov · Nov 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 2 interventional trial (recruiting). This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of chi
ClinicalTrials.gov · Nov 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 1 interventional trial (recruiting). The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
ClinicalTrials.gov · Nov 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 4 interventional trial (recruiting). The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.
ClinicalTrials.gov · Oct 2025View trial ↗ 🧪 TrialInsufficient
Registered observational trial (terminated). This study is designed to compare weight loss outcomes and safety of ESG versus lifestyle modification in patients with obesity who discontinued GLP-1 therapy due to intolerance or suboptimal weight loss.
ClinicalTrials.gov · Sep 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (recruiting). The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll abo
ClinicalTrials.gov · Sep 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 2 interventional trial (recruiting). This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are pursuing fertility sparing. GLP-1RA are a class of medications that mimic the natural hormone glucagon-like peptide-1. These medications trigger the pancreas to release insulin which can help lower blood sugar levels and delay gastric emptying. The recent FDA approval of GLP-1RAs has changed the landscape for pharmacothe
ClinicalTrials.gov · Aug 2025View trial ↗ 🧪 TrialInsufficient
Registered observational trial (enrolling by invitation). This observational study will explore how Wegovy® (Semaglutide) is used in everyday situations, how it might affect things like weight, body mass index (BMI) and waist circumference, and what kind of impact it could have on overall quality of life. The overall purpose of this study is to understand how Wegovy impacts weight when used as part of regular medical care. Participants will be treated with Wegovy as prescribed to the participant by their doctor, in accordance with normal clinical practice. The study will last for about two yea
ClinicalTrials.gov · Jul 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 2 interventional trial (recruiting). Background: People with alcohol use disorder (AUD) often develop metabolic alcohol-associated liver disease (MetALD). MetALD is a term for the heart, liver, obesity, and other issues that can accompany AUD. MetALD can be fatal. An approved weight management drug (Tirzepatide) may be able to help people with AUD and MetALD control their alcohol intake. Objective: To test Tirzepatide in people with AUD and MetALD. Eligibility: People aged 21 years and older with AUD and MetALD. Design: Participants will be screened. They will have a physical
ClinicalTrials.gov · Jul 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (recruiting). The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
ClinicalTrials.gov · Jun 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 1 interventional trial (recruiting). The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.
ClinicalTrials.gov · May 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 4 interventional trial (not yet recruiting). The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head. Adolescents living with obesity, their caregivers, healthcare providers, healthcare systems, policymakers, and payors are now wondering what role health behavior and lifestyle treatment (HBLT) has in terms of body mass index (BMI) reduction, improvements in quality of life and cardiometabolic health, and mitigating nutritional concerns when medications are used. Is intensive HBLT needed or could low in
ClinicalTrials.gov · May 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 2 interventional trial (recruiting). The purpose of this research study is to evaluate what type of treatment will be beneficial for people with Crohn's disease and difficult to treat inflammation in the small bowel. Current therapies are used to control the inflammation due to Crohn's disease in your digestive tract. In some patients, those therapies are not sufficient to fully treat the disease. This objective of this study is to evaluate the efficacy of a different type of therapy, tirzepatide, that may promote healing of the affected intestinal segment. To evaluate the eff
ClinicalTrials.gov · May 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (recruiting). The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to respond to therapy with daily oral LUM-201.
ClinicalTrials.gov · Apr 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 2 interventional trial (completed). This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.
ClinicalTrials.gov · Mar 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 4 interventional trial (recruiting). The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
ClinicalTrials.gov · Mar 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (active not recruiting). This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
ClinicalTrials.gov · Mar 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 4 interventional trial (active not recruiting). This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
ClinicalTrials.gov · Feb 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (active not recruiting). The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
ClinicalTrials.gov · Oct 2024View trial ↗